论文部分内容阅读
CD38, a cell surface enzyme expressed by Multiple Myeloma and Chronic Lymphatic Leukemia cells, is a target antigen for therapeutic antibodies.Nanobodies, single domain antibodies derived from llama heavy chain antibodies, are emerging as promising tumor diagnostics and therapeutics (1, 2).Advantages of Nanobodies versus conventional antibodies include the capacity to bind functional epitopes, a better tissue penetration in vivo, and the facile construction of bi-or multi-specific biologics by genetic fusion.